<DOC>
	<DOC>NCT01257243</DOC>
	<brief_summary>The purpose of this study is evaluate if efficacy of a combination dose of oxomemazine, guaifenesin and potassium iodate is superior than guaifenesin monotherapy in acute cough treatment.</brief_summary>
	<brief_title>Comparison Between Oxomemazine, Guaifenesin and Potassium Iodate Versus Guaifenesin Monotherapy in Acute Cough Treatment</brief_title>
	<detailed_description>STUDY DESIGN - Open-label, superiority, prospective, parallel group, intent to treat trial - Experiment duration: 7 days - 3 visits (days 1, 2 and 7) - Reduction cough symptoms - Adverse events evaluation</detailed_description>
	<mesh_term>Cough</mesh_term>
	<mesh_term>Guaifenesin</mesh_term>
	<mesh_term>Phenylpropanolamine</mesh_term>
	<mesh_term>Chlorpheniramine, phenylpropanolamine drug combination</mesh_term>
	<mesh_term>Potassium iodate</mesh_term>
	<criteria>1. Patients must be able to understand the study procedures agree to participate and give written consent. 2. Patients with productive cough as result an acute URTI (i.e., cold or flu) or allergic cough in the last 10 day. 3. Cough score superior to 3. 1. Pregnancy or risk of pregnancy. 2. Lactation. 3. Fever above 38ยบ C. 4. Patients with bacterial infections of the upper respiratory tract. 5. Any pathology or past medical condition that can interfere with this protocol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>cough</keyword>
	<keyword>symptoms</keyword>
	<keyword>cold</keyword>
	<keyword>flu</keyword>
</DOC>